OCTA Glaucoma Progression evidence from the Diagnostic Innovations in Glaucoma Study, known as DIGS, adds a careful but notable chapter to glaucoma monitoring. For athletes, coaches, and community health readers, the sports lesson is familiar: early warning signs can matter, but a faster signal is not always the same as a cleaner signal. In glaucoma research, that distinction matters because treatment decisions should rest on repeatable evidence, not one scan in isolation.
The newest DIGS data described here came from research already published by October 26, 2026, so the findings are best read retrospectively. They do not prove that OCT angiography should replace optical coherence tomography or visual field testing. They suggest that vessel-density change may appear earlier in some eyes, while classical structural and functional measures still carry clinical weight.
What The DIGS Study Adds To OCTA Glaucoma Progression
OCTA Glaucoma Progression And Earlier Signals
A DIGS cohort study published on October 1, 2026 followed 180 eyes from 116 patients, with a mean age of 67.6 years and a follow-up averaging 5.1 years from January 2015 to April 2023. In that study, OCTA vessel density detected progression earlier than both circumpapillary retinal nerve fiber layer thickness on OCT and standard visual field testing, although OCTA had lower specificity than OCT in stable eyes, according to the DIGS cohort study.
The headline number is useful, but it needs context. Of 180 eyes, 107 eyes, or 59.4%, showed progression by at least one modality. Progression was detected in 32.2% of eyes by OCTA vessel density, 25.0% by OCT cpRNFL thickness, and 32.8% by visual field testing. Among the eyes that progressed, OCTA was the earliest detector in 40 of 107 eyes, or 37.4%. OCT was earliest in 32 eyes, and visual field testing was earliest in 26 eyes.
Where OCT And Visual Fields Fit
Those figures do not push OCT or visual fields to the sideline. In practical terms, they show that each test may be sensitive to a different expression of disease change. OCTA measures vessel-density change, OCT cpRNFL measures structural thinning, and visual field testing captures functional loss. The 2026 DIGS cohort found OCTA gained a 2.3-year lead time over visual field testing, with a 95% confidence interval of 1.3 to 3.2 years. OCT cpRNFL thickness gained 1.5 years over visual fields, with a 95% confidence interval of 0.6 to 2.4 years. The OCTA versus OCT lead time was much smaller at 0.2 years, with a confidence interval crossing zero.
That last comparison is the caution flag. It suggests that OCTA may add earlier information compared with visual fields, but the advantage over OCT structural testing was marginal in this dataset. For clinicians and patients, the signal is promising but not decisive enough to use alone.
What Earlier Detection Means In Practice
Lead Time Without Overclaiming
In sport, reaction time matters only if the athlete can trust the cue. A false step can be costly. Glaucoma imaging has a similar problem. A tool that detects change earlier may help care teams watch high-risk eyes more closely, but lower specificity can mean more false alarms in eyes that are stable. The DIGS study reported specificity of 75.6% for OCT cpRNFL thickness and 68.9% for OCTA vessel density in non-progressing eyes.
That difference does not make OCTA weak. It makes interpretation careful. Earlier detection may be most useful when it agrees with other signs, appears consistently over repeat visits, or fits the patient’s broader risk profile. The evidence supports OCTA as a complementary measure rather than a stand-alone diagnosis or treatment trigger. Readers comparing recent imaging studies may find related context in this review of early OCTA signals.
Early Glaucoma Detection Clues
A separate DIGS cross-sectional study also supports interest in OCTA for early disease. In pre-perimetric and mild perimetric primary open-angle glaucoma, capillary density metrics performed better than RNFL thickness in distinguishing glaucoma from healthy eyes. Whole-image capillary density had an AUROC of 0.83 for pre-perimetric glaucoma, compared with 0.72 for global RNFL thickness, in the cross-sectional DIGS analysis.
At 85% fixed specificity in that study, whole-image capillary density sensitivity for pre-perimetric glaucoma was about 69%, compared with about 62% for global RNFL thickness. These are meaningful differences, but they came from a cross-sectional design. That means the study was strong for comparing diagnostic separation at a point in time, but it was not the same as proving how an individual eye will change over future visits.
Limits, Specificity, And Patient Context
False Positives And Lower Specificity
OCTA Glaucoma Progression research sits at the intersection of promise and measurement noise. Lower specificity matters because glaucoma care often involves long timelines, repeat testing, and decisions that can affect quality of life. A single abnormal vessel-density result may reflect true biological change, but it may also reflect scan quality, segmentation issues, signal strength, or natural test variation. The DIGS findings support attention to OCTA results, not reflexive action based on one image.
This is especially relevant for community eye health conversations. Screening-style messages can make early detection sound simple: find the change, act fast, prevent loss. The research is less tidy. Earlier OCTA signals may create useful lead time, yet that lead time needs confirmation through repeatable patterns and agreement with other clinical findings. For sports families used to return-to-play protocols, the analogy is direct: one data point rarely settles readiness.
Equity Questions In Imaging
The research notes also describe a racial-comparison DIGS analysis published about February 2026. It examined African descent and European descent glaucoma subjects using at least two years of follow-up and at least four visits. The results suggested that baseline values and loss rates may differ by ancestry, which can affect the timing of progression detection with OCT and OCTA.
That finding should be handled with care. It does not mean one imaging method is universally better for one ancestry group. It means interpretation may depend on baseline vessel density, OCT measures, and loss rates. Future work will need to clarify how race, ancestry, ocular anatomy, disease severity, and image quality interact. Community-facing groups, including SGTT, play an important role in grounding discussions about imaging in aspects like access, follow-up, and safety, steering away from hype.
OCTA Glaucoma Progression Evidence From DIGS
What Clinicians Can Reasonably Take From DIGS
The most defensible reading of the DIGS evidence is that OCTA vessel-density metrics can reveal progression signals earlier than visual field testing in some eyes, and may separate early glaucoma from healthy eyes better than RNFL thickness in selected comparisons. The same evidence also shows tradeoffs: specificity was lower than OCT in stable eyes, and the lead-time edge over OCT was marginal in the 2026 cohort.
For patients, the message is not to ask for one favored test and ignore the rest. The safer message is to ask how each test fits the whole record: pressure history, optic nerve appearance, OCT structure, OCTA vessel density, visual fields, and the reliability of repeated measurements. That is an evidence-based path, not a shortcut.
For athletes and active adults, vision is part of performance, independence, and safety. OCTA Glaucoma Progression studies from DIGS suggest that vascular imaging may give clinicians another early signal to weigh. The evidence is encouraging, but the strongest use is complementary: OCTA beside OCT and visual fields, interpreted over time, with uncertainty stated plainly.